Business Context and Reporting Period
Company: Spyre Therapeutics, Inc. (NASDAQ: SYRE)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Spyre is a clinical-stage biotechnology company focused on developing next-generation therapeutics for inflammatory bowel disease (IBD) and rheumatic diseases (RD). The company's strategy relies on three pillars: advancing next-generation monotherapies (SPY001, SPY002, SPY003), evaluating fixed-dose combinations, and expanding its anti-TL1A program (SPY072) into rheumatic indications. The company has no approved products and generates no revenue from product sales.
Key Financial Metrics
| Metric | 2025 (in millions) | 2024 (in millions) |
|---|---|---|
| Total Revenue | $0.0 | $0.0 |
| Net Loss | $(155.2) | $(208.0) |
| Research & Development Expenses | $171.7 | $162.8 |
| General & Administrative Expenses | $47.9 | $45.8 |
| Gain on Sale of IPR&D | $10.0 | $0.0 |
| Interest Income | $24.9 | $21.3 |
| Cash, Cash Equivalents, and Marketable Securities | $756.5 | $601.4 |
| Accumulated Deficit | $(1,127.6) | $(972.4) |
Note: The filing text does not provide specific data for "2025 Q4" as a standalone quarter; the financial data presented above covers the full fiscal year ended December 31, 2025.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $52.8 million (25%) to $155.2 million in 2025 compared to $208.0 million in 2024. This improvement was primarily driven by a $29.8 million decrease in the fair value of the Contingent Value Rights (CVR) liability and a $10.0 million gain on the sale of in-process research and development (IPR&D) assets.
- Operating Expenses: Total operating expenses increased slightly by $1.0 million to $209.6 million. Research and development (R&D) expenses rose by $8.9 million (5%) due to increased clinical development activities for IBD and rheumatic disease programs, partially offset by lower early-stage research costs.
- Liquidity: Cash and marketable securities increased by approximately $155 million to $756.5 million, bolstered by a $296.4 million net proceeds from an underwritten public offering in October 2025 and $14.8 million from at-the-market offerings.
- Non-Operating Income: "Other income, net" improved significantly by $50.2 million, largely due to favorable changes in the CVR liability valuation.
Guidance, Outlook, and Risks
Clinical Development Outlook
- SKYLINE Phase 2 (UC): Initiated in May 2025. Part A (monotherapies) is enrolling; induction data expected in Q2 2026. Part B (combinations) expected to begin enrollment after Part A, with induction data in 2027.
- SKYWAY Phase 2 (Rheumatic Diseases): Initiated in September 2025 for RA, PsA, and axSpA. Topline proof-of-concept data for all three indications expected in Q4 2026.
- Phase 1 Data: Positive interim Phase 1 data for SPY001, SPY002, SPY003, and SPY072 demonstrated favorable safety profiles and extended half-lives supporting potential quarterly or twice-annual dosing.
Management Commentary
Management stated that based on current operating plans, the company has sufficient resources to fund operations for at least one year from the issuance date of the financial statements. However, the company will need to secure additional financing in the future to fund continued R&D and potential commercialization.
Key Risks and Contingencies
- Capital Requirements: The company has never been profitable and expects to incur significant losses for the foreseeable future. Failure to raise additional capital could force delays or discontinuation of development programs.
- Manufacturing and Supply Chain: The company relies on third-party manufacturers, including WuXi Biologics. The BIOSECURE Act (part of the FY 2026 National Defense Authorization Act) poses risks regarding the use of services from designated "biotechnology companies of concern," potentially requiring a switch in manufacturers.
- Regulatory Approval: All product candidates are in clinical or preclinical stages. There is no assurance that clinical trials will be successful or that regulatory approval will be obtained.
- Internal Controls: The company previously identified a material weakness in internal controls over financial reporting in Q4 2024 regarding net loss per share disclosures, which resulted in restatements. Management concluded that internal controls were effective as of December 31, 2025.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the "at least one year" funding statement against current burn rates and upcoming clinical trial costs.
- Manufacturing Strategy: Confirm the status of the company's plan to diversify manufacturing away from Chinese entities in light of the BIOSECURE Act.
- CVR Liability Valuation: Review the assumptions used to value the Contingent Value Rights liability, as changes in this valuation significantly impacted the 2025 net loss.
- Clinical Milestones: Monitor the Q2 2026 data readout for the SKYLINE Phase 2 trial (Part A) and the Q4 2026 readout for the SKYWAY Phase 2 trial.
- Paragon Agreement Obligations: Review the remaining milestone payment obligations to Paragon Therapeutics, which total up to $22.0 million per program.